Abstract:

Ovarian cancer is the gynecological malignant tumor with the highest mortality rate. Because most of the early symptoms are hidden, 70% of patients are already at an advanced stage. The treatment of advanced ovarian cancer is cytoreductive surgery combined with adjuvant chemotherapy. While up to 75% of patients will meet the problem of disease recurrence after standard initial treatment. Almost all the patients with recurrent ovarian cancer will eventually develop resistance to platinum drugs, eventually leading to poor treatment effects and poor prognosis. Apatinib mesylate is a small molecule VEGFR-2 tyrosine kinase inhibitor, which can inhibit tumor angiogenesis and prevent tumor growth and development. This paper reports two cases of platinum resistant recurrent ovarian cancer patients who received Apatinib Mesylate (375 mg, qd, 3 weeks as a treatment cycle) combined with Etoposide (50 mg, qd, oral drugs for 2 weeks, stop drugs for 1 week, 3 weeks as a treatment cycle) treatment. Two cases were evaluated for partial response after treatment. One case had a progression-free survival period of 11.7 months, and the other case has received treatment for 4.3 months which is still under treatment now. Adverse drug reactions can be tolerated, in order to provide an effective treatment plan for clinic.

Key words: Antineoplastic combined chemotherapy protocols, Ovarian neoplasms, Angiogenesis inhibitors, Case reports, Recurrent ovarian neoplasms, Apatinib mesylate